Adjuvant intraoperative photodynamic therapy in experimental colorectal cancer

Abulafi, A. M.; Dejode, M.; Allardice, J. T.; Ansell, J. K.; Rogers, James P.; Williams, Norman S.

doi:10.1002/bjs.1800820212

Cited by 14 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…181-184 The use of PDT in these tumors is still considered experimental as there are not high level data to support the routine use of PDT for these indications at this time. In addition, PDT may have efficacy in treating hepatocellular carcinoma, which remains one of the most common form of cancer worldwide.…”

Section: Clinical Pdtmentioning

confidence: 99%

Photodynamic therapy of cancer: An update

Agostinis

Berg

Cengel

et al. 2011

CA: A Cancer Journal for Clinicians

4,350

3,792

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative particularly in early-stage tumors. It can prolong survival in inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments. With a number of recent technological improvements, PDT has the potential to become integrated into the mainstream of cancer treatment.

show abstract

Section: Clinical Pdtmentioning

confidence: 99%

Photodynamic therapy of cancer: An update

Agostinis

Berg

Cengel

et al. 2011

CA: A Cancer Journal for Clinicians

4,350

3,792

View full text Add to dashboard Cite

show abstract

“…The U.S. FDA approved photofrin-mediated PDT for patients with Barret's esophagus and high grade dysplasia who did not undergo surgery [34] . PDT has been applied to other GI digestival tumors under the stomach [35,36] , cholangiocarcinoma (CG) [37] , with a therapeutic response on unresectable pancreatic cancers [38] , and on colon or rectal cancers [39,40] .…”

Section: Clinical Applications Of Pdt In a Variety Of Human Cancersmentioning

confidence: 99%

Dual roles of nitric oxide in the regulation of tumor cell response and resistance to photodynamic therapy

2015

View full text Add to dashboard Cite

Photodynamic therapy (PDT) against cancer has gained attention due to the successful outcome in some cancers, particularly those on the skin. However, there have been limitations to PDT applications in deep cancers and, occasionally, PDT treatment resulted in tumor recurrence. A better understanding of the underlying molecular mechanisms of PDT-induced cytotoxicity and cytoprotection should facilitate the development of better approaches to inhibit the cytoprotective effects and also augment PDT-mediated cytotoxicity. PDT treatment results in the induction of iNOS/NO in both the tumor and the microenvironment. The role of NO in cytotoxicity and cytoprotection was examined. The findings revealed that NO mediates its effects by interfering with a dysregulated pro-survival/anti-apoptotic NF-κB/Snail/YY1/RKIP loop which is often expressed in cancer cells. The cytoprotective effect of PDT-induced NO was the result of low levels of NO that activates the pro-survival/anti-apoptotic NF-κB, Snail, and YY1 and inhibits the anti-survival/pro-apoptotic and metastasis suppressor RKIP. In contrast, PDT-induced high levels of NO result in the inhibition of NF-kB, Snail, and YY1 and the induction of RKIP, all of which result in significant anti-tumor cytotoxicity. The direct role of PDT-induced NO effects was corroborated by the use of the NO inhibitor, l-NAME, which reversed the PDT-mediated cytotoxic and cytoprotective effects. In addition, the combination of the NO donor, DETANONOate, and PDT potentiated the PDT-mediated cytotoxic effects. These findings revealed a new mechanism of PDT-induced NO effects and suggested the potential therapeutic application of the combination of NO donors/iNOS inducers and PDT in the treatment of various cancers. In addition, the study suggested that the combination of PDT with subtoxic cytotoxic drugs will result in significant synergy since NO has been shown to be a significant chemo-immunosensitizing agent to apoptosis.

show abstract

“…In the study groups it was 17-33% compared with 83-100% in the control groups. Those results suggest that PDT with use of Photofrin® may reduce local recurrence following surgical tumor excision in analyzed mice model[91].Bugaj et al tested induction of necrosis in human CRC xenografts in athymic nude mice after photosensitization with di-L-arginine protoporphyrinate (PPArg2), one of the new class of water soluble porphyrin photosensitizers, developed by research group from Military University of Technology in Warsaw [92]. Under irradiation with red light (λ = 632 nm, fluence 150 J/cm2) 24 and 72 h after intravenous administration of 10 mg/kg of PPArg2 extensive tumor necrosis was detected.…”

mentioning

confidence: 81%